Long-Range Enhancers are Required to Maintain …diabetes.diabetesjournals.org/content/diabetes/early/2007/10/17/db... · Islet-Specific Gene Expression ABSTRACT Objective: Islet-specific

Long-Range Enhancers are Required to Maintain Expression of the Autoantigen IGRP in Adult Mouse Islets In Vivo

Yingda Wang1, Brian P. Flemming

1, Cyrus C. Martin

1, Shelley R. Allen

1, Jay Walters

2,

James K. Oeser1, John C. Hutton

2 and Richard M. O’Brien

1

1Department of Molecular Physiology and Biophysics, Vanderbilt University Medical School,

Nashville, Tennessee 37232 2Barbara Davis Center for Childhood Diabetes, University of Colorado at Denver and Health Sciences

Center, Aurora, Colorado 80045

Running Title: Islet-Specific Gene Expression

Corresponding Author: Richard M. O’Brien

Department of Molecular Physiology and Biophysics 761 PRB

Vanderbilt University Medical School Nashville, TN 37232-0615

E-mail: [email protected]

Received for publication 19 January 2007 and accepted in revised form 11 October 2007.

Additional information for this article can be found in an online appendix at http://diabetes.diabetesjournals.org.

Diabetes Publish Ahead of Print, published online October 17, 2007

Copyright American Diabetes Association, Inc., 2007

Islet-Specific Gene Expression

ABSTRACT Objective: Islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) is selectively expressed in islet beta cells and is a major autoantigen in both mouse and human Type I diabetes. This study describes the use of a combination of transgenic and transfection approaches to characterize the gene regions that confer the islet-specific expression of IGRP. Research Design and Methods: Transgenic mice were generated containing the IGRP promoter sequence from -306, -911 or -3911 to +3 ligated to a LacZ reporter gene. Transgene expression was monitored by XGal staining of pancreatic tissue. Results & Conclusions: In all these transgenic mice robust LacZ expression was detected in newborn mouse islets but expression became mosaic as animals aged, suggesting that additional elements are required for the maintenance of IGRP gene expression. VISTA analyses identified two conserved regions in the distal IGRP promoter and one in the third intron. Transfection experiments demonstrated that all three regions confer enhanced luciferase reporter gene expression in βTC-3 cells when ligated to a minimal IGRP promoter. A transgene containing all three conserved regions was generated by using a bacterial recombination strategy to insert a LacZ cassette into exon 5 of the IGRP gene. Transgenic mice containing a 15 kbp fragment of the IGRP gene were then generated. This transgene conferred LacZ expression in newborn mouse islets, however, expression was still suppressed as animals aged, suggesting that long-range enhancers 5' or 3' of the IGRP gene are required for the maintenance of IGRP gene expression in adult mice. KEY WORDS glucose-6-phosphatase; autoantigen; diabetes; pancreas; transcription; promoter ABBREVIATIONS G6PC, glucose-6-phosphatase catalytic subunit; IGRP, islet-specific glucose-6-phosphatase catalytic subunit-related protein; UGRP, ubiquitously expressed glucose-6-phosphatase catalytic subunit-related protein; G6P, glucose-6-phosphate; NOD, Non Obese Diabetic; CAT, chloramphenicol acetyltransferase; X-gal, 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside; HIT, hamster insulinoma tumor; TK, thymidine kinase; TSS, transcription start site; IRES, internal ribosome entry site; BAC, bacterial artificial chromosome; EGFP, enhanced green fluorescent protein; FRT, FLP recombination target; Tet, tetracycline-resistance cassette.

2


he glucose-6-phosphatase catalytic subunit (G6PC) gene family is comprised of three members; G6PC,

which is predominantly expressed in liver and kidney and plays a major role in glucose homeostasis (1); G6PC2, an islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) of uncertain function (2-4) and G6PC3, a ubiquitously expressed glucose-6-phosphatase catalytic subunit-related protein (UGRP) that confers low glucose-6-phosphatase activity to a broad range of tissues (5-8). The encoded proteins exhibit around 50% sequence identity, exhibit a common 9 transmembrane domain topology and are all localized to the endoplasmic reticulum (5; 6). IGRP is principally confined to the β cells of the islet (9) and is a candidate for the low glucose-6-phosphatase enzyme activity detected in this tissue (2; 4). In combination with glucokinase, IGRP could create a substrate cycle and thus modulate β cell glycolytic flux and therefore glucose-stimulated insulin secretion (10). Indeed, a global knockout of the IGRP gene results in a mild metabolic phenotype characterized by a ~15% decrease in fasting blood glucose (4), consistent with a role for IGRP in glucose cycling. However, overexpression of IGRP by transient transfection of fibroblast or endocrine cell lines seems to have little (11), if any (2; 3; 12), impact on G6P hydrolysis in cell homogenates. This raises the question as to whether IGRP requires other cellular factors to exhibit activity or whether it is a catalytically-inert regulatory subunit of a metabolic process. IGRP was recently identified as a target of cell-mediated autoimmunity in Type 1 diabetes both in mice (13-16) and humans (17). Up to 40% of the CD8 positive T cells infiltrating islets in Non Obese Diabetic (NOD) mice recognize an immunodominant peptide epitope (aa 206-214) within IGRP

(18) and it is also a target of CD4 positive T cells (19). Significantly, in vivo administration of select IGRP epitope peptides to NOD mice has been shown to abrogate or delaythe disease process (14). However, whether there is a causal relationship between autoimmunity toward IGRP and type 1 diabetes is unclear. Indeed, a recent study in mice suggests that autoimmunity toward IGRP is a secondary event (20). Our work has focused on identifying the transcription factors that control IGRP gene expression with the goal of identifying novel, islet-enriched transcription factors important for pancreatic development and/or function (3; 21-23). We believe this approach is reasonable given that similar work, focused on other islet-specific genes, has led to the identification of such proteins (24-26). A key step in the identification of such factors is the definition of the minimal IGRP gene sequence necessary for mimicking the expression pattern of the endogenous IGRP gene. We have previously demonstrated that the -306 to +3 region of the mouse IGRP promoter confers high fusion gene expression in islet-derived cell lines (21-23; 27) and is sufficient to initiate transgene expression in mouse islets, predominantly in β cells, at the expected time in development, around embryonic day 14 (28). However, unlike the endogenous IGRP gene, expression of this transgene was markedly suppressed in adult mouse islets suggesting that additional cis-acting elements in the IGRP gene are required for the maintenance of IGRP gene expression in adult mice. In this study we describe the identification of enhancers in the IGRP promoter and third intron, however, the expression of a transgene containing these enhancers was still suppressed in adult mice. These data suggest that long-range enhancers 5' or 3' of the IGRP gene are required for the

T

3


maintenance of IGRP gene expression in adult mice. RESEARCH DESIGN AND METHODS Fusion gene plasmid construction. The construction of IGRP-LacZ fusion genes containing mouse promoter sequence between -306, -911 and -3911 and +3, relative to the transcription start site (TSS), is described in the Online-Only Appendix (available at http://diabets.diabetesjournals.org) as is the use of bacterial recombination to introduce a LacZ-containing cassette into a bacterial artificial chromosome (BAC) clone containing the IGRP gene. The isolation and ligation of the putative IGRP enhancers A, B, C, E & F (Figs. 5 & 7) to a minimal IGRP-luciferase fusion gene is also described in the Online Only Appendix. Animal care. The animal housing and surgical facilities used for the mice in these studies met American Association for the Accreditation of Laboratory Animal Care standards. All animal protocols were approved by the Vanderbilt University Medical Center Animal Care Committee. Food (Purina Mouse Chow 5001; Ralston-Purina, St. Louis, MO) and water were provided ad libitum. Generation, breeding and genotyping of transgenic mice. Transgenic mice were generated by the joint Vanderbilt Cancer Center/Diabetes Research and Training Center Transgenic Animal/Embryonic Stem Cell Core Facility. The generation of transgenic mice expressing the -306 IGRP-LacZ fusion gene has been described (28). The -911 IGRP-LacZ, -3911 IGRP-LacZ fusion genes and the IGRP-BAC transgene were isolated as described in the Online-Only Appendix. Transgenic mice were produced by microinjection of 3-10 picoliters of a 3 ng/µl solution of the transgenes into the pronuclei of one cell embryos derived from

B6D2F1 females. Embryos were then transferred into the oviducts of pseudopregant ICR females. Transgenic founders were bred with B6D2F1 mice (The Jackson Laboratory, Bar Harbor, ME) and offspring genotyped using real-time PCR in conjunction with the following primers: 5'-ACGCTGATTGAAGCAGAAGCC-3' and 5'-ATCGGTCAGACGATTCATTGGC-3' and the Bio-Rad iQ SYBR Green Supermix (Hercules, CA). The detection of LacZ expression by 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) staining of mouse tissues was performed at 4° C as previously described (28). Cell culture, transient transfection and luciferase assays. Mouse pancreatic islet β cell-derived βTC-3 cells were cultured and co-transfected with 0.5 µg of an expression vector encoding SV40-Renilla luciferase (Promega) and 2 µg of the indicated firefly luciferase plasmids using the lipofectamine reagent (GibcoBRL) as previously described (22). Following transfection βTC-3 cells were harvested by trypsin digestion and then resuspended in passive lysis buffer (Promega). After two cycles of freeze/thawing, firefly and Renilla luciferase activity were then assayed using the Dual Luciferase Assay Kit (Promega). To correct for variations in transfection efficiency, results are expressed as the ratio of firefly:Renilla luciferase activity. Fusion gene expression was assessed in three separate experiments each using an independent preparation of each plasmid, transfected in triplicate. RESULTS The proximal IGRP promoter is insufficient for the maintenance of transgene expression in adult mice. Previous studies with transgenic mice in which LacZ gene expression was under the control of the -306

4


to +3 IGRP promoter region demonstrated that this region was sufficient to drive LacZ expression in newborn mouse islets (28). As seen with the endogenous IGRP gene (2; 9), transgene expression initiated at the expected time in development, around embryonic day 14, and was detected predominantly in β cells (28). However, unlike the endogenous IGRP gene (3), LacZ gene expression was also detected in the cerebellum (28). In addition, in adult mice expression of the endogenous IGRP gene is maintained in all beta cells (4; 9) whereas LacZ expression was almost completely absent in the transgenic adult mouse islets (28). Figure 1 shows a more detailed analysis of the time course of this loss of LacZ expression in these animals. Clear pancreatic LacZ expression was readily detected in newborn mice but only mosaic islet expression was detected by three weeks (Fig. 1). This mosaic expression was maintained at six weeks but was very rarely detected at 6 months (Fig. 1). In contrast, LacZ expression in the cerebellum was maintained in adult animals (Fig. 1). A second independent founder line of mice also demonstrated a loss of islet transgene expression in adult animals (data not shown). Transfection experiments in βTC-3 cells (28) have shown that the -911 to +3 IGRP promoter region confers ~25% higher fusion gene expression than the -306 to + 3 region. In addition, the promoter sequence between -500 and -306 is well conserved between mouse and human IGRP (data not shown). We therefore generated transgenic mice in which LacZ reporter gene expression was under the control of the -911 to +3 IGRP promoter region. As with the -306/+3 promoter region, the -911/+3 promoter region drove LacZ expression in newborn mouse islets (Fig. 2). Moreover, as with the endogenous IGRP gene, LacZ expression was not detected in the brain (Fig. 2). Nevertheless, transgene expression was again markedly reduced in adult mouse islets (Fig.

2). Figure 2 shows an analysis of the time course of this loss of LacZ expression. Clear pancreatic LacZ expression was detected in newborn mice but only mosaic islet expression was detected by three weeks (Fig. 2). This mosaic expression was maintained at six weeks but was not apparent at 6 months (Fig. 2). Although a faint blue color was detected following whole mount staining of pancreata isolated from 6 month old mice this appeared to be non-specific since pancreatic sections were negative (Fig. 2). A second independent founder line of mice similarly showed a loss of transgene expression in adult animals (data not shown). These data suggest that the proximal IGRP promoter between -911 and +3 is not sufficient for the maintenance of IGRP gene expression in adult mice and that cis-acting elements elsewhere in the IGRP gene are required. Only limited genomic sequence was available when the -306 and -911 IGRP-LacZ transgenic mice were generated but BAC clones containing the entire mouse (AL929170) and human (AC069137) IGRP genes were subsequently described. Sequence alignment of the mouse and human IGRP promoter regions between -5000 and +1 using the IntelliGenetics, Inc. (Mountain View, CA) IFIND program identified a conserved region between -1800 and -2500 (data not shown). We therefore generated transgenic mice in which LacZ gene expression was under the control of the -3911 to +3 IGRP promoter region that encompassed the conserved -1800/-2500 region. Five independent founder lines of mice were analyzed. As with the -306/+3 and -911/+3 promoter regions, the -3911/+3 promoter drove clear LacZ expression in newborn mouse pancreas (Fig. 3A). Figure 3 shows an analysis of LacZ expression in the -3911 IGRP-LacZ transgenic mice over time. In contrast to the -306 and -911 IGRP-LacZ transgenic mice, transgene expression was clearly detected in adult mouse islets (Fig. 3A

5


& B). However, with the exception of Line 38, only mosaic islet expression was detected at three weeks and the proportion of cells expressing the transgene decreased over time (Fig. 3B). Figure 3B shows two panels of pancreas sections isolated from the same Line 38 mouse. These demonstrate that Line 38 islets were detected in which transgene expression remained on in most cells (left panel), however, even with this founder line, islets were also detected in which a mosaic pattern of expression was apparent (right panel). These results suggest that the presence of the conserved -1800/-2500 region and the proximal promoter are not sufficient for the maintenance of transgene expression in adult mouse islets. Interestingly, this demonstration of mosaic transgene expression in multiple animals reinforces the concept that the β cell population within adult islets is not homogeneous (29). In some lines of the -3911 IGRP-LacZ mice transgene expression was also detected in the brain, mainly in the cerebellum but also in other areas (Fig. 3A). The loss of brain expression in the mice expressing the -911/+3 IGRP-LacZ transgene initially suggested that elements required for restricting appropriate IGRP tissue-specific expression were located between -911 and -306. The re-emergence of brain transgene expression in some lines of -3911/+3 mice indicates that this is not the case. Instead brain expression may simply reflect the effect of random integration. The tendency to detect expression in the cerebellum may be explained by the high expression of Pax-6 in this tissue (30), a factor that is critical for IGRP promoter activity (27). The IGRP promoter and third intron contain transcriptional enhancers. To identify candidate regions of the IGRP gene that might contain elements required for the maintenance of IGRP gene expression another sequence alignment was performed but this time using

the VISTA program (31; 32) in conjunction with mouse and human IGRP gene sequence 10 kbp 5' and 3' of the IGRP TSS (Fig. 4). This analysis identified two conserved regions in the mouse IGRP promoter, located between approximately (-1800 and -2500) and (-3700 and -4700), and a conserved non-promoter region, located 3' of exon 3 between approximately +3050 and +3830 (Fig. 4). These regions are found in the same relative location in the human IGRP gene except for the conserved -3700/-4700 region which is located ~6000 bp 5' of the TSS in the human IGRP gene. This explains why an alignment of the proximal mouse and human 5000 bp promoter regions using the IntelliGenetics, Inc. IFIND program missed this region. We hypothesized these regions might conceivably represent transcriptional enhancers required for the maintenance of IGRP gene expression in adult mice. To address this hypothesis these regions, designated enhancers A, B and C (Fig. 4), were isolated and ligated 5' of an IGRP-luciferase fusion gene containing the proximal human IGRP promoter sequence between -324 and +3 (Fig. 5). Luciferase expression directed by these fusion genes was then analyzed by transient transfection of βTC-3 cells. Figure 5 shows that all three regions enhanced reporter gene expression beyond that driven by the -324/+3 IGRP-luciferase fusion gene alone. In addition, this effect was independent of orientation consistent with the definition of an enhancer (33). However, when the +3050 to +3830 region was ligated 3' of the -324/+3 IGRP-luciferase fusion gene it did not enhance reporter gene expression, which is inconsistent with the strict definition of an enhancer whose actions are orientation and location independent (33). Generation of an IGRP-BAC transgene by bacterial recombination. Based on these results further transgenic mice were generated to assess whether the combination of the

6


proximal IGRP promoter with enhancers A, B and C were sufficient to maintain IGRP transgene expression in adult mice. Because the results of the fusion gene analyses suggested that spacing affected enhancer C function (Fig. 5), a transgene was generated by using bacterial recombination to introduce a cassette into exon 5 of the IGRP gene such that the spacing between the IGRP TSS and enhancer C was the same as found in the native IGRP gene (Fig. 6A). The IGRP gene was located within a BAC clone and the cassette comprised an enhanced green fluorescent protein (EGFP) cDNA, an internal ribosome entry site (IRES), a cDNA encoding a β-galactosidase-neomycin resistance fusion protein, a FRT (FLP recombination target) site, a tetracycline-resistance cassette (Tet) and a second FRT site (Fig. 6A). The EGFP cDNA was inserted in frame with the coding sequence of IGRP exon 5. After recombination the Tet cassette was removed using FLP recombinase. Bacterial recombination was then used to shuttle the region of the IGRP gene from -5000 to +10051 from the modified BAC clone to the plasmid pGEM7 (Fig. 6A). This region contains enhancers A, B and C in addition to the proximal promoter, all exons and introns and the targeting cassette (Fig. 6A). Transgenic mice containing this region, minus the pGEM7 plasmid backbone, were then generated. Three independent founder lines of mice were analyzed. EGFP fluorescence was not detected suggesting that the EGFP domain within the IGRP-EGFP fusion protein may not fold correctly. However, as with the -306, -911 and -3911 IGRP-LacZ fusion genes, in all three mouse lines the IGRP-BAC transgene drove clear LacZ expression in newborn pancreas (Fig. 6B). However, variable results were seen in adult mice with either no (line 12), mosaic (Line 15) or strong (Line 16) LacZ expression detected in islets by three weeks of age (Fig. 6B & C). These

variable results probably reflect the consequences of random integration but they suggest that the presence of the proximal promoter in combination with enhancers A, B and C are still not sufficient for the maintenance of transgene expression in adult mouse islets. The genomic region 3' of the IGRP gene contains two enhancers. Based on these results we expanded the search for additional putative enhancers that might contribute to IGRP gene expression by using the UCSC Genome Browser (http://genome.ucsc.edu/index.html) to locate conserved regions present in the entire ~13,900 bp and ~12,100 bp intervals between the neighboring Spbc25 (5') and Abcb11 (3') genes, respectively. This analysis identified one additional region, designated Region D (data not shown) of substantial sequence conservation between mice and rats 5' of the IGRP gene, however, this region is not conserved in humans and the IGRP gene is not expressed in rats (3). In contrast, four blocks of conserved sequence were identified 3' of the IGRP gene (data not shown). Two of these conserved regions are located close to the Abcb11 gene so we hypothesized that they are likely to be involved in the regulation of Abcb11 gene expression. In contrast, the other two conserved regions are located closer to the IGRP gene, ~900 bp and ~2500 bp 3' of the last exon, exon 5, between approximately (+8771 and +9372) and (+10622 and +11022), respectively, relative to the TSS (Fig. 4). We hypothesized that these regions, designated E and F, might represent transcriptional enhancers required for the maintenance of IGRP gene expression. To address this hypothesis, these regions were isolated and ligated 5' of an IGRP-luciferase fusion gene containing the proximal human IGRP promoter region located between -324 and +3 (Fig. 7). Luciferase expression directed by these fusion

7


genes was then analyzed by transient transfection of βTC-3 cells. Figure 7 shows that regions E and F enhanced reporter gene expression beyond that driven by the -324/+3 IGRP-luciferase fusion gene alone. However, this effect was dependent on orientation and location (Fig. 7). Thus, region E only enhanced luciferase expression in one orientation and when region F was ligated 3' of the -324/+3 IGRP-luciferase fusion gene it did not enhance reporter gene expression (Fig. 7). Thus neither enhancer E nor F meet the strict definition of an enhancer whose actions are orientation and location independent (33). Intronic enhancers have previously been identified in other genes whose expression are enriched in islets including glucagon (34), islet amyloid polypeptide (35), HNF-6 (36) and Pax-6 (37). However, to the best of our knowledge this is the first report of an enhancer located 3' of an islet-enriched gene. DISCUSSION Sequence comparisons (Fig. 4) and transfection studies (Figs. 5 & 7) have identified five putative enhancers in the IGRP gene. Transgenic mice containing IGRP promoter sequence from -306 to +3 (Fig. 1) or -911 to +3 (Fig. 2), that lack all of these enhancers, and mice containing IGRP promoter sequence from -3911 to +3, that encompasses only enhancer A (Fig. 3), all demonstrated strong LacZ expression in newborn mouse islets but mosaic expression in adult mouse islets. Interestingly this decrease in transgene expression between newborn and adult islets coincides with the major changes in pancreatic gene expression that occur at this time (38). Strong LacZ expression was also observed in islets in newborn IGRP-BAC mice, in which the transgene contains enhancers A, B, C and E, but again expression was not consistently maintained in adult islets (Fig. 6). Region F is absent from the IGRP-BAC transgene and while region E is present its spacing relative

to the IGRP TSS is altered (Fig. 6A). We hypothesize that this may explain why expression of the IGRP-BAC transgene is not uniformly maintained in adult mouse islets in vivo despite the presence of enhancers A, B and C. However, we cannot rule out the existence of additional enhancers located 5' or 3' beyond the Spbc25 and Abcb11 genes that flank the IGRP gene. Ideally, we would like to generate transgenic mice containing all five enhancers and then determine whether this was now sufficient for the maintenance of transgene expression in adult islets. However, transfection studies (Figs. 5 & 7) suggest that this will require the insertion of a reporter gene into the IGRP locus in a manner such that the distance between enhancers C, E and F and the TSS is precisely maintained. Unfortunately, the IGRP gene only spans ~8000 bp (21) and VISTA analyses (Fig. 4) reveal multiple other conserved areas within the IGRP gene in addition to these five enhancers. Therefore, although the technology is available to insert an IRES-LacZ cassette within the IGRP gene without altering the distance between enhancers C, E and F and the TSS (Fig. 6), it does not appear that this can be done without disrupting conserved sequences. Based on this limitation we can only conclude that, because enhancers A, B and C are not sufficient for the uniform maintenance of IGRP gene expression in adult mouse islets, long-range enhancers, presumably including enhancers E and F, must also be required. Far upstream enhancers, located >100 kbp from the TSS, have been shown to be important for the expression of several genes including Sox9 and Bmp2 (39; 40). The importance of such long-range enhancers has been emphasized from the results of recent genome wide association studies that identified genetic variants that increase the susceptibility to developing type 2 diabetes (41-44). One such variant is located in a region that contains no

8


known genes or microRNAs. This region is located 125 kbp upstream of the CDKN2A gene and may represent an enhancer that modulates CDKN2A expression (41-44). The observation that the IGRP promoter sequence from -306 to +3 fails to drive transgene expression in all adult islet beta cells is surprising in that this region of the IGRP promoter binds NeuroD/BETA2 (23), Pax-6 (27), Pdx-1 (27) and MafA (Martin & O'Brien, unpublished observations), the same factors that bind the -668 to +1 region of rat insulin II promoter (45). As with the -306/+3 IGRP promoter (Fig. 1), this region of the rat insulin II promoter confers islet-enriched transgene expression (46; 47) but, in contrast with the IGRP promoter, it confers sustained transgene expression in adult mice (46). The molecular explanation for this difference is unclear especially since insulin and IGRP fusion genes that incorporate these promoter regions confer similar levels of reporter gene expression in islet-derived cell lines (22). ACKNOWLEDGMENTS We thank Peer B. Jacobson, David R. Powell, Hong Chen, Kenneth A. Platt,

Clayton Matthews, Barbara Bergman, Karl Hilliker and Karen L. Rufus for assistance with this project and Maureen Gannon for helpful comments on the manuscript. We thank Doug Mortlock, Ron Chandler and Kelly Chandler for extensive help with the bacterial recombination method. We also thank Cathleen Pettepher, Managing Director of the Vanderbilt Cancer Center/Diabetes Research and Training Center Transgenic Animal/Embryonic Stem Cell Core Facility, for generating the transgenic mice and Shimon Efrat for providing the βTC-3 cell line. Research in the laboratory of R.O’B. was supported by NIH grant DK061645. Research in the laboratory of J. C. H. was supported by the American Diabetes Association (9901-116), and the Barbara Davis Center Diabetes and Endocrinology Research Center (P30 DK57516). The Vanderbilt Diabetes Research and Training Center is funded by NIH grant P60 DK20593-24 and the Vanderbilt-Ingram Cancer Center is funded by NIH grant P30 CA68485-06. Cyrus Martin was supported by the Vanderbilt Viruses, Nucleic Acids and Cancer Training Program (5T32 CA09385-17).

9


REFERENCES 1. Van Schaftingen E, Gerin I: The glucose-6-phosphatase system. Biochem J 362:513-532, 2002 2. Arden SD, Zahn T, Steegers S, Webb S, Bergman B, O'Brien RM, Hutton JC: Molecular cloning of a

pancreatic islet-specific glucose-6-phosphatase catalytic subunit-related protein. Diabetes 48:531-542, 1999

3. Martin CC, Bischof LJ, Bergman B, Hornbuckle LA, Hilliker C, Frigeri C, Wahl D, Svitek CA, Wong R, Goldman JK, Oeser JK, Lepretre F, Froguel P, O'Brien RM, Hutton JC: Cloning and Characterization of the Human and Rat Islet-Specific Glucose-6-Phosphatase Catalytic Subunit-Related Protein (IGRP) Genes. J Biol Chem 276:25197-25207, 2001

4. Wang Y, C. MC, Oeser JK, Sarkar S, McGuinness OP, Hutton JC, O'Brien RM: Deletion of the Gene Encoding the Islet-Specific Glucose-6-Phosphatase Catalytic Subunit-Related Protein Autoantigen Results in a Mild Metabolic Phenotype. Diabetologia 50:774-778, 2007

5. Martin CC, Oeser JK, Svitek CA, Hunter SI, Hutton JC, O'Brien RM: Identification and Characterization of a Human cDNA and Gene Encoding a Ubiquitously Expressed Glucose-6-Phosphatase Catalytic Subunit-Related Protein. J Mol Endocrinol 29:205-222, 2002

6. Boustead JN, Martin CC, Oeser JK, Svitek CA, Hunter SI, Hutton JC, O'Brien RM: Identification and characterization of a cDNA and the gene encoding the mouse ubiquitously expressed glucose-6-phosphatase catalytic subunit-related protein. J Mol Endocrinol 32:33-53, 2004

7. Shieh JJ, Pan CJ, Mansfield BC, Chou JY: A glucose-6-phosphate hydrolase, widely expressed outside the liver, can explain age-dependent resolution of hypoglycemia in glycogen storage disease type Ia. J Biol Chem 278:47098-47103, 2003

8. Wang Y, Oeser JK, Yang C, Sarkar S, Hackl SI, Hasty AH, McGuinness OP, Paradee W, Hutton JC, Powell DR, O'Brien RM: Deletion of the gene encoding the ubiquitously expressed glucose-6-phosphatase catalytic subunit-related protein (UGRP)/glucose-6-phosphatase catalytic subunit-beta results in lowered plasma cholesterol and elevated glucagon. J Biol Chem 281:39982-39989, 2006

9. Hutton JC, Eisenbarth GS: A pancreatic beta-cell-specific homolog of glucose-6-phosphatase emerges as a major target of cell-mediated autoimmunity in diabetes. Proc Natl Acad Sci U S A 100:8626-8628, 2003

10. Newgard CB, Lu D, Jensen MV, Schissler J, Boucher A, Burgess S, Sherry AD: Stimulus/secretion coupling factors in glucose-stimulated insulin secretion: insights gained from a multidisciplinary approach. Diabetes 51 Suppl 3:S389-393, 2002

11. Petrolonis AJ, Yang Q, Tummino PJ, Fish SM, Prack AE, Jain S, Parsons TF, Li P, Dales NA, Ge L, Langston SP, Schuller AG, An WF, Tartaglia LA, Chen H, Hong SB: Enzymatic characterization of the pancreatic islet-specific glucose-6-phosphatase-related protein (IGRP). J Biol Chem 279:13976-13983, 2004

12. Shieh JJ, Pan CJ, Mansfield BC, Chou JY: In islet-specific glucose-6-phosphatase-related protein, the beta cell antigenic sequence that is targeted in diabetes is not responsible for the loss of phosphohydrolase activity. Diabetologia 48, 2005

13. Lieberman SM, Evans AM, Han B, Takaki T, Vinnitskaya Y, Caldwell JA, Serreze DV, Shabanowitz J, Hunt DF, Nathenson SG, Santamaria P, DiLorenzo TP: Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci U S A 100:8384-8388, 2003

10


14. Han B, Serra P, Amrani A, Yamanouchi J, Maree AF, Edelstein-Keshet L, Santamaria P: Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide. Nat Med 11:645-652, 2005

15. Han B, Serra P, Yamanouchi J, Amrani A, Elliott JF, Dickie P, Dilorenzo TP, Santamaria P: Developmental control of CD8 T cell-avidity maturation in autoimmune diabetes. J Clin Invest 115:1879-1887, 2005

16. Wong CP, Li L, Frelinger JA, Tisch R: Early autoimmune destruction of islet grafts is associated with a restricted repertoire of IGRP-specific CD8+ T cells in diabetic nonobese diabetic mice. J Immunol 176:1637-1644, 2006

17. Yang J, Danke NA, Berger D, Reichstetter S, Reijonen H, Greenbaum C, Pihoker C, James EA, Kwok WW: Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects. J Immunol 176:2781-2789, 2006

18. Trudeau JD, Kelly-Smith C, Verchere CB, Elliott JF, Dutz JP, Finegood DT, Santamaria P, Tan R: Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest 111:217-223, 2003

19. Mukherjee R, Wagar D, Stephens TA, Lee-Chan E, Singh B: Identification of CD4+ T cell-specific epitopes of islet-specific glucose-6-phosphatase catalytic subunit-related protein: a novel beta cell autoantigen in type 1 diabetes. J Immunol 174:5306-5315, 2005

20. Krishnamurthy B, Dudek NL, McKenzie MD, Purcell AW, Brooks AG, Gellert S, Colman PG, Harrison LC, Lew AM, Thomas HE, Kay TW: Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J Clin Invest 116:3258-3265, 2006

21. Ebert DH, Bischof LJ, Streeper RS, Chapman SC, Svitek CA, Goldman JK, Mathews CE, Leiter EH, Hutton JC, O'Brien RM: Structure and promoter activity of an islet-specific glucose-6- phosphatase catalytic subunit-related gene. Diabetes 48:543-551, 1999

22. Bischof LJ, Martin CC, Svitek CA, Stadelmaier BT, Hornbuckle LA, Goldman JK, Oeser JK, Hutton JC, O’Brien RM: Characterization of the Mouse Islet-Specific Glucose-6-Phosphatase Catalytic Subunit-Related Protein Gene Promoter by In Situ Footprinting. Correlation with Fusion Gene Expression in the Islet Derived bTC-3 and Hamster Insulinoma Tumor Cell Lines. Diabetes 50:502-514, 2001

23. Martin CC, Svitek CA, Oeser JK, Henderson E, Stein R, O'Brien RM: Upstream Stimulatory Factor (USF) and NeuroD/BETA2 Contribute toIslet-Specific Glucose-6-Phosphatase Catalytic Subunit Related Protein (IGRP)Gene Expression. Biochem J 371:675-686, 2003

24. Yamaoka T, Itakura M: Development of pancreatic islets (review). Int J Mol Med 3:247-261, 1999 25. Bonner-Weir S: Islet growth and development in the adult. J Mol Endocrinol 24:297-302., 2000 26. Bramblett DE, Huang HP, Tsai MJ: Pancreatic islet development. Adv Pharmacol 47:255-315, 2000 27. Martin CC, Oeser JK, O'Brien RM: Differential regulation of islet-specific glucose-6-phosphatase

catalytic subunit-related protein gene transcription by Pax-6 and Pdx-1. J Biol Chem 279:34277-34289, 2004

28. Frigeri C, Martin CC, Svitek CA, Oeser JK, Hutton JC, Gannon M, O’Brien RM: The Proximal Islet-Specific Glucose-6-Phosphatase Catalytic Subunit Related Protein (IGRP) Autoantigen Promoter is Sufficient to Initiate but not Maintain Transgene Expression in Mouse Islets In Vivo. Diabetes 53:1754-1764, 2004

29. Samaras SE, Cissell MA, Gerrish K, Wright CV, Gannon M, Stein R: Conserved sequences in a tissue-specific regulatory region of the pdx-1 gene mediate transcription in Pancreatic beta cells: role for hepatocyte nuclear factor 3 beta and Pax6. Mol Cell Biol 22:4702-4713, 2002

11


30. Callaerts P, Halder G, Gehring WJ: PAX-6 in development and evolution. Annu Rev Neurosci 20:483-532, 1997

31. Frazer KA, Pachter L, Poliakov A, Rubin EM, Dubchak I: VISTA: computational tools for comparative genomics. Nucleic Acids Res 32:W273-279, 2004

32. Mayor C, Brudno M, Schwartz JR, Poliakov A, Rubin EM, Frazer KA, Pachter LS, Dubchak I: VISTA : visualizing global DNA sequence alignments of arbitrary length. Bioinformatics 16:1046-1047, 2000

33. Blackwood EM, Kadonaga JT: Going the distance: a current view of enhancer action. Science 281:60-63, 1998

34. Zhou L, Nian M, Gu J, Irwin DM: Intron 1 sequences are required for pancreatic expression of the human proglucagon gene. Am J Physiol Regul Integr Comp Physiol 290:R634-641, 2006

35. Ekawa K, Nishi M, Ohagi S, Sanke T, Nanjo K: Cloning of mouse islet amyloid polypeptide gene and characterization of its promoter. J Mol Endocrinol 19:79-86, 1997

36. Poll AV, Pierreux CE, Lokmane L, Haumaitre C, Achouri Y, Jacquemin P, Rousseau GG, Cereghini S, Lemaigre FP: A vHNF1/TCF2-HNF6 cascade regulates the transcription factor network that controls generation of pancreatic precursor cells. Diabetes 55:61-69, 2006

37. Kleinjan DA, Seawright A, Childs AJ, van Heyningen V: Conserved elements in Pax6 intron 7 involved in (auto)regulation and alternative transcription. Dev Biol 265:462-477, 2004

38. Scearce LM, Brestelli JE, McWeeney SK, Lee CS, Mazzarelli J, Pinney DF, Pizarro A, Stoeckert CJ, Jr., Clifton SW, Permutt MA, Brown J, Melton DA, Kaestner KH: Functional genomics of the endocrine pancreas: the pancreas clone set and PancChip, new resources for diabetes research. Diabetes 51:1997-2004, 2002

39. Kleinjan DA, van Heyningen V: Long-range control of gene expression: emerging mechanisms and disruption in disease. Am J Hum Genet 76:8-32, 2005

40. Chandler RL, Chandler KJ, McFarland KA, Mortlock DP: Bmp2 transcription in osteoblast progenitors is regulated by a distant 3' enhancer located 156.3 kilobases from the promoter. Mol Cell Biol 27:2934-2951, 2007

41. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, Prokunina-Olsson L, Ding CJ, Swift AJ, Narisu N, Hu T, Pruim R, Xiao R, Li XY, Conneely KN, Riebow NL, Sprau AG, Tong M, White PP, Hetrick KN, Barnhart MW, Bark CW, Goldstein JL, Watkins L, Xiang F, Saramies J, Buchanan TA, Watanabe RM, Valle TT, Kinnunen L, Abecasis GR, Pugh EW, Doheny KF, Bergman RN, Tuomilehto J, Collins FS, Boehnke M: A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316:1341-1345, 2007

42. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, Hughes TE, Groop L, Altshuler D, Almgren P, Florez JC, Meyer J, Ardlie K, Bengtsson Bostrom K, Isomaa B, Lettre G, Lindblad U, Lyon HN, Melander O, Newton-Cheh C, Nilsson P, Orho-Melander M, Rastam L, Speliotes EK, Taskinen MR, Tuomi T, Guiducci C, Berglund A, Carlson J, Gianniny L, Hackett R, Hall L, Holmkvist J, Laurila E, Sjogren M, Sterner M, Surti A, Svensson M, Svensson M, Tewhey R, Blumenstiel B, Parkin M, Defelice M, Barry R, Brodeur W, Camarata J, Chia N, Fava M, Gibbons J, Handsaker B, Healy C, Nguyen K, Gates C, Sougnez C, Gage D, Nizzari M, Gabriel SB, Chirn GW, Ma Q, Parikh H, Richardson D, Ricke D, Purcell S: Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331-1336, 2007

43. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, Timpson NJ, Perry JR, Rayner NW, Freathy RM, Barrett JC, Shields B, Morris AP, Ellard S, Groves CJ, Harries LW,

12


Marchini JL, Owen KR, Knight B, Cardon LR, Walker M, Hitman GA, Morris AD, Doney AS, Burton PR, Clayton DG, Craddock N, Deloukas P, Duncanson A, Kwiatkowski DP, Ouwehand WH, Samani NJ, Todd JA, Donnelly P, Davison D, Easton D, Evans D, Leung HT, Spencer CC, Tobin MD, Attwood AP, Boorman JP, Cant B, Everson U, Hussey JM, Jolley JD, Knight AS, Koch K, Meech E, Nutland S, Prowse CV, Stevens HE, Taylor NC, Walters GR, Walker NM, Watkins NA, Winzer T, Jones RW, McArdle WL, Ring SM, Strachan DP, Pembrey M, Breen G, St Clair D, Caesar S, Gordon-Smith K, Jones L, Fraser C, Green EK, Grozeva D, Hamshere ML, Holmans PA, Jones IR, Kirov G, Moskvina V, Nikolov I, O'Donovan M C, Owen MJ, Collier DA, Elkin A, Farmer A, Williamson R, McGuffin P, Young AH, Ferrier IN, Ball SG, Balmforth AJ, Barrett JH, Bishop DT, Iles MM, Maqbool A, Yuldasheva N, Hall AS, Braund PS, Dixon RJ, Mangino M, Stevens S, Thompson JR, Bredin F, Tremelling M, Parkes M, Drummond H, Lees CW, Nimmo ER, Satsangi J, Fisher SA, Forbes A, Lewis CM, Onnie CM, Prescott NJ, Sanderson J, Mathew CG, Barbour J, Mohiuddin MK, Todhunter CE, Mansfield JC, Ahmad T, Cummings FR, Jewell DP, Webster J, Brown MJ, Lathrop GM, Connell J, Dominiczak A, Braga Marcano CA, Burke B, Dobson R, Gungadoo J, Lee KL, Munroe PB, Newhouse SJ, Onipinla A, Wallace C, Xue M, Caulfield M, Farrall M, Barton A, Bruce IN, Donovan H, Eyre S, Gilbert PD, Hider SL, Hinks AM, John SL, Potter C, Silman AJ, Symmons DP, Thomson W, Worthington J, Dunger DB, Widmer B, Newport M, Sirugo G, Lyons E, Vannberg F, Hill AV, Bradbury LA, Farrar C, Pointon JJ, Wordsworth P, Brown MA, Franklyn JA, Heward JM, Simmonds MJ, Gough SC, Seal S, Stratton MR, Rahman N, Ban M, Goris A, Sawcer SJ, Compston A, Conway D, Jallow M, Rockett KA, Bumpstead SJ, Chaney A, Downes K, Ghori MJ, Gwilliam R, Hunt SE, Inouye M, Keniry A, King E, McGinnis R, Potter S, Ravindrarajah R, Whittaker P, Widden C, Withers D, Cardin NJ, Ferreira T, Pereira-Gale J, Hallgrimsdottir IB, Howie BN, Su Z, Teo YY, Vukcevic D, Bentley D, Compston A, Ouwehand NJ, Samani MR, Isaacs JD, Morgan AW, Wilson GD, Ardern-Jones A, Berg J, Brady A, Bradshaw N, Brewer C, Brice G, Bullman B, Campbell J, Castle B, Cetnarsryj R, Chapman C, Chu C, Coates N, Cole T, Davidson R, Donaldson A, Dorkins H, Douglas F, Eccles D, Eeles R, Elmslie F, Evans DG, Goff S, Goodman S, Goudie D, Gray J, Greenhalgh L, Gregory H, Hodgson SV, Homfray T, Houlston RS, Izatt L, Jackson L, Jeffers L, Johnson-Roffey V, Kavalier F, Kirk C, Lalloo F, Langman C, Locke I, Longmuir M, Mackay J, Magee A, Mansour S, Miedzybrodzka Z, Miller J, Morrison P, Murday V, Paterson J, Pichert G, Porteous M, Rahman N, Rogers M, Rowe S, Shanley S, Saggar A, Scott G, Side L, Snadden L, Steel M, Thomas M, Thomas S, McCarthy MI, Hattersley AT: Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316:1336-1341, 2007

44. The Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447:661-678, 2007

45. Melloul D, Marshak S, Cerasi E: Regulation of insulin gene transcription. Diabetologia 45:309-326, 2002

46. Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, Shelton KD, Lindner J, Cherrington AD, Magnuson MA: Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem 274:305-315, 1999

47. Gannon M, Shiota C, Postic C, Wright CV, Magnuson M: Analysis of the Cre-mediated recombination driven by rat insulin promoter in embryonic and adult mouse pancreas. Genesis 26:139-142, 2000

13


FIGURE LEGENDS Figure 1. The -306 to +3 IGRP promoter region is insufficient for maintaining transgene expression in adult mouse islets in vivo. Panel A: Whole mount X-gal staining of pancreas and brain isolated from -306/+3 IGRP-LacZ transgenic mice at the indicated ages. The punctate pattern of pancreatic staining represents islet-specific expression (28) whereas blue staining in the intestinal lumen is due to β-galactosidase activity in endogenous gut flora. Representative pictures are shown. The pictures are 50X magnifications. P, pancreas; St, stomach; Sp, spleen. Panel B: X-gal staining of sections prepared from pancreas isolated from 306/+3 IGRP-LacZ transgenic mice at the indicated ages. The sections were counter-stained with eosin. Representative pictures are shown. The pictures are 100X magnifications. I, islet. Figure 2. The -911 to +3 IGRP promoter region is insufficient for maintaining transgene expression in adult mouse islets in vivo. Panel A: Whole mount X-gal staining of pancreas and brain isolated from -911/+3 IGRP-LacZ transgenic mice at the indicated ages. Representative pictures are shown. The pictures are 50X magnifications. P, pancreas; St, stomach; Int, intestine. Panel B: X-gal staining of sections prepared from pancreas isolated from -911/+3 IGRP-LacZ transgenic mice at the indicated ages. The sections were counter-stained with eosin. Representative pictures are shown. The pictures are 100X magnifications. I, islet. Figure 3. The -3911 to +3 IGRP promoter region is insufficient for maintaining transgene expression in adult mouse islets in vivo. Panel A: Whole mount X-gal staining of pancreas and brain isolated from -3911/+3 IGRP-LacZ transgenic mice at the indicated ages. Representative pictures are shown. The pictures are 50X magnifications. P, pancreas; St, stomach; Sp, spleen; Int, intestine. Panel B: X-gal staining of sections prepared from pancreas isolated from -3911/+3 IGRP-LacZ transgenic mice at the indicated ages. The sections were counter-stained with eosin. Representative pictures are shown. The pictures are 100X magnifications. I, islet. Figure 4. Sequence conservation between the mouse and human IGRP genes. A VISTA Browser plot (31; 32) of 22.5 kbp of mouse and human IGRP gene sequence. The IGRP TSS is at bp 10,000. The level of conservation is displayed on the vertical axis. Conserved regions above the level of 70%/100 bp are highlighted in red. The location of five putative enhancers are indicated. Figure 5. Identification of enhancers in the IGRP promoter and third intron. βTC-3 cells were transiently co-transfected, as described in Research Design and Methods, with an expression vector encoding Renilla luciferase (0.5 µg) and the indicated firefly luciferase fusion genes (2 µg). Following transfection, cells were incubated for 18-20 hr in serum-containing medium. The cells were then harvested and luciferase activity assayed as described in Research Design and Methods. Results are presented as the ratio of firefly:Renilla luciferase activity and represent the mean of 3 experiments ± S.E.M., each using an independent preparation of each fusion gene plasmid.

14


Figure 6. The proximal IGRP promoter and enhancers A, B and C are insufficient for maintaining transgene expression in adult mouse islets in vivo. Panel A: Diagramatic representation of the IGRP gene and a targeting construct used in the construction of the IGRP-BAC transgene. The location of the five IGRP exons and five putative enhancers (A, B, C, E & F) are indicated. The targeting vector contains an enhanced green fluorescent protein (EGFP) cDNA, an internal ribosome entry site (IRES), a cDNA encoding a β-galactosidase (βGal)-neomycin (Neo) resistance fusion protein, two FRT (FLP recombination target) sites, and a tetracycline-resistance cassette (Tet). Bacterial recombination was used to insert the targeting vector into IGRP exon 5. The IGRP gene sequence between -5000 and +10051, containing the multi-component targeting cassette, was then transferred to the pGEM7 plasmid by a second round of bacterial recombination. Panel B: Whole mount X-gal staining of pancreas and brain isolated from IGRP-BAC transgenic mice at the indicated ages. Representative pictures are shown. The pictures are 50X magnifications. P, pancreas; St, stomach. Panel C: X-gal staining of sections prepared from pancreas isolated from IGRP-BAC transgenic mice at the indicated ages. The sections were counter-stained with eosin. Representative pictures are shown. The pictures are 100X magnifications. I, islet. Figure 7. Identification of enhancers 3' of the IGRP gene. βTC-3 cells were transiently co-transfected, as described in Research Design and Methods, with an expression vector encoding Renilla luciferase (0.5 µg) and the indicated firefly luciferase fusion genes (2 µg). Following transfection, cells were incubated for 18-20 hr in serum-containing medium. The cells were then harvested and luciferase activity assayed as described in Research Design and Methods. Results are presented as the ratio of firefly:Renilla luciferase activity and represent the mean of 3 experiments ± S.E.M., each using an independent preparation of each fusion gene plasmid.

15


16


17


18


19


20


21


22


23


24

Long-Range Enhancers are Required to Maintain …diabetes.diabetesjournals.org/content/diabetes/early/2007/10/17/db... · Islet-Specific Gene Expression ABSTRACT Objective: Islet-specific

Documents